Minsu Jang Selected Research

conessine

4/2018	Conessine Treatment Reduces Dexamethasone-Induced Muscle Atrophy by Regulating MuRF1 and Atrogin-1 Expression.
2/2018	Conessine treatment reduces dexamethasone-induced muscle atrophy by regulating MuRF1 and atrogin-1 expression.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Minsu Jang Research Topics

Disease

5	Neoplasms (Cancer) 07/2021 - 01/2017
3	COVID-19 12/2021 - 01/2020
2	Muscular Atrophy (Muscle Atrophy) 04/2018 - 02/2018
2	Atrophy 04/2018 - 02/2018
1	Lacrimal Apparatus Diseases (Epiphora) 01/2021
1	Macular Edema 10/2020
1	Low Tension Glaucoma 10/2020
1	Neoplasm Metastasis (Metastasis) 01/2017

Drug/Important Bio-Agent (IBA)

2	UbiquitinIBA 04/2018 - 02/2018
2	Dexamethasone (Maxidex)FDA LinkGeneric 04/2018 - 02/2018
2	Ligases (Synthetase)IBA 04/2018 - 02/2018
2	conessineIBA 04/2018 - 02/2018
1	Antiviral Agents (Antivirals)IBA 12/2021
1	AdiponectinIBA 07/2021
1	Proteins (Proteins, Gene)FDA Link 07/2021
1	Catechin (Z 7300)IBA 03/2021
1	epigallocatechin gallate (epigallocatechin-3-gallate)IBA 03/2021
1	TeaIBA 03/2021
1	Type A Botulinum Toxins (Botox)FDA Link 01/2021
1	Retinaldehyde (Retinal)IBA 10/2020
1	Synthetic Prostaglandins (Prostaglandin Analogues)IBA 10/2020
1	VaccinesIBA 01/2020
1	theaflavinIBA 01/2020
1	CRISPR-Associated Protein 9IBA 12/2019
1	belotecanIBA 12/2017
1	Topoisomerase I InhibitorsIBA 12/2017
1	CamptothecinIBA 12/2017
1	NADPH Oxidase 4IBA 01/2017

Therapy/Procedure

1	Therapeutics 01/2018